{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:39:45Z","timestamp":1778675985099,"version":"3.51.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple primary malignant neoplasms (MPMNs) are difficult to identify from the metastasis or recurrence of malignant tumors. Additionally, the genetic mutations in each primary tumor vary from each other; therefore, it is critical to explore potential abnormal genes. Next-generation sequencing (NGS) technology has emerged as a reliable approach for detecting mutated genes in primary tumors and can provide several targeted therapeutic options for patients with MPMNs. Here, we report a case of metachronous multiple primary malignant neoplasm (MMPMN) patient with primary ovarian and breast cancer. Targeted NGS genetic profiling revealed a rare EGFR T790M mutation in this patient\u2019s primary breast tumor tissue, which has only been reported previously in breast cancer (BC). Based on the NGS results, osimertinib was recommended for this patient. Although this patient did not receive osimertinib because of gastrointestinal hemorrhage, this case highlights the significance of NGS technology in the diagnosis and treatment of MPMNs.<\/jats:p>","DOI":"10.3389\/fonc.2023.1204041","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T14:07:09Z","timestamp":1690207629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Next-generation sequencing-based detection in a breast MMPMN patient with EGFR T790M mutation: a rare case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Huiyun","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3892\/ol.2022.13604","article-title":"Analysis of primary synchronous breast invasive ductal carcinoma and lung adenocarcinoma with next-generation sequencing: A case report","volume":"25","author":"Wu","year":"2023","journal-title":"Oncol Lett"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196103\/04)14:2<221::aid-cncr2820140202>3.0.co;2-6","article-title":"Multiple primary malignant neoplasms. I. Introduction and presentation of data","volume":"14","author":"Moertel","year":"1961","journal-title":"Cancer-Am Cancer Soc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0782","article-title":"Multiple cancer prevalence: a growing challenge in long-term survivorship","volume":"16","author":"Mariotto","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200008000-00011","article-title":"Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms","volume":"23","author":"Aydiner","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134398","article-title":"The epidermal growth factor receptor (EGFR \/ HER-1) gatekeeper mutation T790M is present in European patients with early breast cancer","volume":"10","author":"Bemanian","year":"2015","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.200613","article-title":"Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.08.015","article-title":"A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition","volume":"22","author":"Zhang","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000513904","article-title":"Combination of crizotinib and osimertinib in T790M+ EGFR-mutant non-small cell lung cancer with emerging MET amplification post-osimertinib progression in a 10-year survivor: A case report","volume":"14","author":"Blasi","year":"2021","journal-title":"Case Rep Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.21037\/atm.2019.04.37","article-title":"EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib","volume":"7","author":"Ma","year":"2019","journal-title":"Ann Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7150\/thno.57706","article-title":"EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb2914","article-title":"Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability","volume":"13","author":"Li","year":"2021","journal-title":"Sci Transl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/21655979.2021.1890382","article-title":"Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer","volume":"12","author":"Zheng","year":"2021","journal-title":"Bioengineered"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000701","article-title":"Molecular testing for EGFR mutations and ALK rearrangements in the cytological specimens from the patients with non-small cell lung cancer","volume":"27","author":"Wang","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2015_052","article-title":"Molecular analysis of EGFR gene in different types of tumor material from NSCLC patients","volume":"62","author":"Dolesova","year":"2015","journal-title":"Neoplasma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.04.006","article-title":"First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials","volume":"133","author":"Schuler","year":"2019","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.602762","article-title":"Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI osimertinib: conventional ways and immune checkpoint inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0554-5","article-title":"Treatment of EGFR T790M-positive non-small cell lung cancer","volume":"13","author":"Choo","year":"2018","journal-title":"Target Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23136936","article-title":"Acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer: how do we overcome it","volume":"23","author":"Bertoli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.10.021","article-title":"Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib","volume":"141","author":"Zhao","year":"2020","journal-title":"Lung Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154945","article-title":"Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy","volume":"132","author":"Halima","year":"2022","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103191","DOI":"10.1016\/j.critrevonc.2020.103191","article-title":"A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4\/6 inhibitors in ER+\/HER2- breast cancer","volume":"157","author":"Servetto","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.910264","article-title":"Case report: next-generation sequencing-based detection in A patient with three synchronous primary tumors","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1204041\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T14:07:16Z","timestamp":1690207636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1204041\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":28,"alternative-id":["10.3389\/fonc.2023.1204041"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1204041","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"article-number":"1204041"}}